\
&
Contact us
This was 1 year ago
LocationBrussels
The European Commission organises a conference for policymakers, industry experts and innovators to explore the transformative power of data and its impact on EU competitiveness.
Taking place one year before the Data Act becomes applicable, this event provides an opportunity to discuss key initiatives that will shape the future of Europe's data economy. The Data Act aims to establish a unified framework for data sharing across the EU, emphasising fair access and user rights. Amongst others, the Act grants IoT device owners the right to control the use of data generated by their devices.
The event will provide a unique platform for stakeholders to discuss the opportunities and challenges related to the Data Act, focusing on how increased data access can foster Common European Data Spaces, drive innovation and boost EU competitiveness.
For more information on the agenda and to register, please visit the event website. Please note that due to the limited capacity of the venue, registrations are subject to validation by the organisers.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.